WORLDSymposium 2022 New Treatment Award

WORLDSymposium 2022 recognized two important achievements in therapy for lysosomal diseases for attaining regulatory approval. The WORLDSymposium 2022 New Treatment Award was presented to Sanofi Genzyme for avalglucosidase alfa-ngpt (Nexviazyme®) which provided clinical data meriting approval by the U.S. Food and Drug Administration (FDA), and to JCR Pharmaceuticals for pabinafusp alfa (IZCARGO®), which provided clinical data meriting approval by the Ministry of Health, Labour and Welfare (MHLW) in Japan. WORLDSymposium 2022 New Treatment Award were presented on Thursday, February 10, 2022, at 7:30 AM followed by a full day of Contemporary Forum abstract presentations.